title: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
abstract: Linezolid (Zyvox), the first of a new class of antibiotics, the oxazolidinones, is approved for treatment of Gram-positive bacterial infections, including resistant strains. The disposition of linezolid in human volunteers was determined, after a 500-mg (100-microCi) oral dose of [(14)C]linezolid. Radioactive linezolid was administered as a single dose, or at steady-state on day 4 of a 10-day, 500-mg b.i.d. regimen of unlabeled linezolid (n = 4/sex/regimen). Mean recovery of radioactivity in excreta was 93.8 +/- 1.1% (range 91.2-95.2%, n = 15), of which 83.9 +/- 3.3% (range 76.7-88.4%) was in urine and 9.9 +/- 3.4% (range 5.3-16.9%) was in feces. There was no major difference in rate or route of excretion of radioactivity by dose regimen. Linezolid was excreted primarily intact, and as two inactive, morpholine ring-oxidized metabolites, PNU-142586 and PNU-142300. Other minor metabolites were characterized by high-performance liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry and (19)F NMR spectroscopy. After the single radioactive dose, linezolid was the major circulating drug-related material accounting for about 78% (male) and 93% (female) of the radioactivity area under the curve (AUC). PNU-142586 (T(max) of 3-5 h) accounted for about 26% (male) and 9% (female) of the radioactivity AUC. PNU-142300 (T(max) of 2-3 h) accounted for about 7% (male) and 4% (female) of the radioactivity AUC. Overall, mean linezolid and PNU-142586 exposures at steady-state were similar across sex. In conclusion, linezolid circulates in plasma mainly as parent drug. Linezolid and two major, inactive metabolites account for the major portion of linezolid disposition, with urinary excretion representing the major elimination route. Formation of PNU-142586 was the rate-limiting step in the clearance of linezolid.
authors.affiliation: Global Metabolism and Investigative Sciences, Pharmacia Corporation, 301 Henrietta St., Kalamazoo, MI 49007, USA. john.g.slatter@pharmacia.com
authors.forename: J G
authors.initials: JG
authors.lastname: Slatter
authors.forename: D J
authors.initials: DJ
authors.lastname: Stalker
authors.forename: K L
authors.initials: KL
authors.lastname: Feenstra
authors.forename: I R
authors.initials: IR
authors.lastname: Welshman
authors.forename: J B
authors.initials: JB
authors.lastname: Bruss
authors.forename: J P
authors.initials: JP
authors.lastname: Sams
authors.forename: M G
authors.initials: MG
authors.lastname: Johnson
authors.forename: P E
authors.initials: PE
authors.lastname: Sanders
authors.forename: M J
authors.initials: MJ
authors.lastname: Hauer
authors.forename: P E
authors.initials: PE
authors.lastname: Fagerness
authors.forename: R P
authors.initials: RP
authors.lastname: Stryd
authors.forename: G W
authors.initials: GW
authors.lastname: Peng
authors.forename: E M
authors.initials: EM
authors.lastname: Shobe
mesh_terms: D000081:Acetamides / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000328:Adult; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D005243:Feces / Q000737:chemistry; D005260:Female; D005462:Fluorine Radioisotopes; D006207:Half-Life; D006801:Humans; D007553:Isotope Labeling; D000069349:Linezolid; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D023303:Oxazolidinones / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D013056:Spectrophotometry, Ultraviolet; D014915:Whole-Body Counting
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D005462:Fluorine Radioisotopes; D023303:Oxazolidinones; D000069349:Linezolid